Neuren Pharmaceuticals
Home
About Us
Company Overview
Company Values
Board of Directors
Management
Corporate Directory
Product development
Product Development Pipeline
The science behind Neuren's products
Trofinetide (also known as NNZ-2566) in Rett Syndrome
Trofinetide (also known as NNZ-2566) in Fragile X Syndrome
NNZ-2591 in Phelan-McDermid syndrome
NNZ-2591 in Angelman syndrome
NNZ-2591 in Pitt Hopkins syndrome
NNZ-2591 in Prader-Willi syndrome
Investor Information
Welcome
Share Price Information
Shareholder Services
Investor presentations, audio, video
Corporate Governance
Analyst Coverage
Corporate Directory
News & Reports
ASX Announcements
Annual and Interim Reports
Scientific presentations
Email Alerts
Publications
Contact Us
Contact Us
Email Alerts
ASX Announcements
Annual and Interim Reports
Scientific presentations
Email Alerts
Publications
Home
>
News & Reports
>
Annual and Interim Reports
Font Smaller
Font larger
Print Page
Annual and Interim Reports
annual report
view the neuren pharmaceuticals
2021
interactive annual report
Annual and Interim Reports
24-Feb-2022
Preliminary Final Report and 2021 Full Year Accounts
Preliminary Final Report and 2021 Full Year Accounts
25-Aug-2021
Half Yearly Report and Accounts
Half Yearly Report and Accounts
24-Feb-2021
2020 Interactive Annual Report
2020 Interactive Annual Report
24-Feb-2021
Preliminary Final Report and 2020 full year accounts
Preliminary Final Report and 2020 full year accounts
28-Aug-2020
2019 Interactive Annual Report
2019 Interactive Annual Report
26-Aug-2020
Half Yearly Report and Accounts
Half Yearly Report and Accounts
4-May-2020
2018 Interactive Annual Report
2018 Interactive Annual Report
26-Feb-2020
Appendix 4E and 2019 full year accounts
Appendix 4E and 2019 full year accounts
28-Aug-2019
Half Yearly Report and Accounts
Half Yearly Report and Accounts
27-Feb-2019
Preliminary Final Report and statutory accounts
Preliminary Final Report and statutory accounts
Click here for archives